NASDAQ:CLBS - Caladrius Biosciences Stock Price, News, Headlines & Rumors Sign in or create an account to add this stock to your watchlist. Get Started $5.16 +0.13 (+2.58 %) (As of 08/16/2018 04:00 PM ET)Previous Close$5.03Today's Range$5.01 - $5.1652-Week Range$2.63 - $11.65Volume24,700 shsAverage Volume169,720 shsMarket Capitalization$49.11 millionP/E Ratio-2.88Dividend YieldN/ABeta0.82 Company ProfileAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Caladrius Biosciences, Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company's lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient's own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company is focused on commencing The Sanford Project: T-Rex Study, a Phase II prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate its Treg product candidate, CLBS03, in adolescents with recent onset T1D. The Company plans to develop its product candidate, CLBS12, in Japan, which is an autologous therapy that derives its cells from peripheral blood through apheresis. Receive CLBS News and Ratings via Email Sign-up to receive the latest news and ratings for CLBS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Miscellaneous health & allied services, not elsewhere classified Sub-IndustryN/A SectorMedical SymbolNASDAQ:CLBS CUSIPN/A Webwww.caladrius.com Phone908-842-0100 Debt Debt-to-Equity RatioN/A Current Ratio8.86 Quick Ratio8.86 Price-To-Earnings Trailing P/E Ratio-2.88 Forward P/E Ratio-2.24 P/E GrowthN/A Sales & Book Value Annual Sales$35.28 million Price / Sales1.42 Cash FlowN/A Price / CashN/A Book Value$5.30 per share Price / Book0.97 Profitability EPS (Most Recent Fiscal Year)($1.78) Net Income$22.97 million Net MarginsN/A Return on Equity-33.99% Return on Assets-27.21% Miscellaneous Employees22 Outstanding Shares9,730,000Market Cap$49.11 million Caladrius Biosciences (NASDAQ:CLBS) Frequently Asked Questions What is Caladrius Biosciences' stock symbol? Caladrius Biosciences trades on the NASDAQ under the ticker symbol "CLBS." How were Caladrius Biosciences' earnings last quarter? Caladrius Biosciences Inc (NASDAQ:CLBS) announced its earnings results on Friday, August, 10th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.64) by $0.07. View Caladrius Biosciences' Earnings History. When is Caladrius Biosciences' next earnings date? Caladrius Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, November, 8th 2018. View Earnings Estimates for Caladrius Biosciences. What price target have analysts set for CLBS? 2 analysts have issued 12-month price objectives for Caladrius Biosciences' stock. Their forecasts range from $7.00 to $12.00. On average, they anticipate Caladrius Biosciences' stock price to reach $9.50 in the next twelve months. This suggests a possible upside of 84.1% from the stock's current price. View Analyst Price Targets for Caladrius Biosciences. What is the consensus analysts' recommendation for Caladrius Biosciences? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Caladrius Biosciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Caladrius Biosciences. Who are some of Caladrius Biosciences' key competitors? Some companies that are related to Caladrius Biosciences include Catasys (CATS), BioRestorative Therapies (BRTX), Pacific Health Care Organization common stock (PFHO), MYnd Analytics (MYND), Hooper Holmes (HPHW) and American Caresource (GNOW). Who are Caladrius Biosciences' key executives? Caladrius Biosciences' management team includes the folowing people: David J. Mazzo Ph.D., Chief Executive Officer, Independent Director (Age 59)Joseph Talamo, Chief Financial Officer, Senior Vice President (Age 47)Douglas W. Losordo M.D., Chief Medical Officer (Age 58)Gregory B. Brown M.D., Director (Age 64)Richard J. Berman J.D., Independent Director (Age 75)Drew Bernstein CPA., , Independent Director (Age 59)Martyn D. Greenacre, Independent Director (Age 75)Steven Mark Klosk, Independent Director (Age 60) Has Caladrius Biosciences been receiving favorable news coverage? News articles about CLBS stock have trended somewhat positive recently, Accern Sentiment reports. The research group identifies positive and negative media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Caladrius Biosciences earned a news impact score of 0.02 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 46.20 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days. View Recent Headlines for Caladrius Biosciences. Who are Caladrius Biosciences' major shareholders? Caladrius Biosciences' stock is owned by a number of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (2.02%). View Institutional Ownership Trends for Caladrius Biosciences. Which institutional investors are buying Caladrius Biosciences stock? CLBS stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. View Insider Buying and Selling for Caladrius Biosciences. How do I buy shares of Caladrius Biosciences? Shares of CLBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Caladrius Biosciences' stock price today? One share of CLBS stock can currently be purchased for approximately $5.16. How big of a company is Caladrius Biosciences? Caladrius Biosciences has a market capitalization of $49.11 million and generates $35.28 million in revenue each year. The biotechnology company earns $22.97 million in net income (profit) each year or ($1.78) on an earnings per share basis. Caladrius Biosciences employs 22 workers across the globe. How can I contact Caladrius Biosciences? Caladrius Biosciences' mailing address is 106 ALLEN ROAD FOURTH FLOOR, BASKING RIDGE NJ, 07920. The biotechnology company can be reached via phone at 908-842-0100 or via email at [email protected] MarketBeat Community Rating for Caladrius Biosciences (NASDAQ CLBS)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 230 (Vote Outperform)Underperform Votes: 175 (Vote Underperform)Total Votes: 405MarketBeat's community ratings are surveys of what our community members think about Caladrius Biosciences and other stocks. Vote "Outperform" if you believe CLBS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLBS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 8/16/2018 by MarketBeat.com StaffFeatured Article: What are the Different Types of Leveraged Buyouts?